Abbott’s HIV/AIDS Drug Patents Challenged by PUBPAT
I am skeptical about the prospects for invalidating patents on drugs, particularly important or blockbuster drugs. I also question whether anti-patent do-gooders in the biotech and pharma space are...
View ArticleUS Oncologists Report Crucial Cancer Drug Shortages
The mantra of the anti-patent community is nearly in unison on the issue of patented drugs. Of course, everyone wants drugs to be developed, but no one wants to pay the exorbitant prices charged for...
View ArticleValid but Not Infringed, Merck’s Loses Blockbuster Nasonex®
Last week, on Friday, June 15, 2012, Merck (NYSE: MRK) announced the U.S. District Court for the District of New Jersey (Judge Peter G. Sheridan) ruled against the company on the issue of patent...
View ArticleThe Problem of Counterfeit and Black Market Drugs
Americans cannot be expect to either personally or through their health insurance bear the burden associated with solely providing the return on investment required by investors to prompt...
View ArticleA Primer on Paragraph IV Certifications: Into the Belly of the Hatch-Waxman...
In a moment of extreme weakness, I agreed to Gene’s request to doing a primer on Paragraph IV Certifications under the Drug Price Competition and Patent Term Restoration Act, commonly referred to as...
View ArticleWinning the Drug Development Debate
We create two new companies around academic inventions every day of the year. The critical role such companies play in drug development is clear. The successful integration of public research...
View ArticleDrug Product Pipelines: Potential Blockbusters?
Drug manufactures spend billions of dollars in R&D and it takes years to get FDA approvals and patent protection. It is vital that these companies keep a vibrant and thriving product pipeline to...
View Article
More Pages to Explore .....